AstraZeneca (AZN) Competitors $70.87 +0.49 (+0.70%) Closing price 04:00 PM EasternExtended Trading$70.72 -0.15 (-0.21%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AZN vs. NVO, NVS, SNY, GSK, TAK, ARGX, ONC, BNTX, TEVA, and SMMTShould you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novo Nordisk A/S (NVO), Novartis (NVS), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry. AstraZeneca vs. Novo Nordisk A/S Novartis Sanofi GSK Takeda Pharmaceutical argenx Beigene BioNTech Teva Pharmaceutical Industries Summit Therapeutics Novo Nordisk A/S (NYSE:NVO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Does the MarketBeat Community prefer NVO or AZN? Novo Nordisk A/S received 371 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 60.00% of users gave AstraZeneca an outperform vote. CompanyUnderperformOutperformNovo Nordisk A/SOutperform Votes43461.74% Underperform Votes26938.26% AstraZenecaOutperform Votes6360.00% Underperform Votes4240.00% Does the media prefer NVO or AZN? In the previous week, Novo Nordisk A/S had 17 more articles in the media than AstraZeneca. MarketBeat recorded 45 mentions for Novo Nordisk A/S and 28 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.13 beat Novo Nordisk A/S's score of 0.91 indicating that AstraZeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 29 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive AstraZeneca 18 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, NVO or AZN? Novo Nordisk A/S has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Which has stronger valuation & earnings, NVO or AZN? Novo Nordisk A/S has higher revenue and earnings than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovo Nordisk A/S$303.14B1.02$14.64B$3.3820.31AstraZeneca$54.98B3.97$7.04B$2.4928.27 Do analysts recommend NVO or AZN? Novo Nordisk A/S presently has a consensus target price of $135.00, suggesting a potential upside of 96.68%. AstraZeneca has a consensus target price of $88.00, suggesting a potential upside of 25.04%. Given Novo Nordisk A/S's higher possible upside, equities research analysts clearly believe Novo Nordisk A/S is more favorable than AstraZeneca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novo Nordisk A/S 2 Sell rating(s) 5 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.38AstraZeneca 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10 Is NVO or AZN more profitable? Novo Nordisk A/S has a net margin of 34.81% compared to AstraZeneca's net margin of 13.01%. Novo Nordisk A/S's return on equity of 84.68% beat AstraZeneca's return on equity.Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S34.81% 84.68% 26.29% AstraZeneca 13.01%32.23%12.31% Is NVO or AZN a better dividend stock? Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.4%. AstraZeneca pays an annual dividend of $2.06 per share and has a dividend yield of 2.9%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. AstraZeneca pays out 82.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Do institutionals & insiders believe in NVO or AZN? 11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryNovo Nordisk A/S beats AstraZeneca on 13 of the 21 factors compared between the two stocks. Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AZN vs. The Competition Export to ExcelMetricAstraZenecaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$218.27B$6.46B$5.34B$8.46BDividend Yield2.96%2.65%5.29%4.18%P/E Ratio31.148.6826.9019.78Price / Sales3.97256.30409.22138.41Price / Cash11.7965.8538.2534.64Price / Book5.346.386.764.54Net Income$7.04B$143.23M$3.22B$247.85M7 Day Performance0.61%3.09%1.39%1.31%1 Month Performance-1.85%2.84%9.42%9.43%1 Year Performance-7.49%0.31%20.29%10.33% AstraZeneca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AZNAstraZeneca2.2147 of 5 stars$70.87+0.7%$88.00+24.2%-8.1%$219.79B$54.98B31.3683,500Positive NewsShort Interest ↑NVONovo Nordisk A/S4.6805 of 5 stars$67.26-1.3%$135.00+100.7%-48.8%$301.83B$303.14B20.4454,400NVSNovartis2.3664 of 5 stars$112.77+0.2%$123.38+9.4%+12.2%$238.21B$53.22B19.18101,700Positive NewsShort Interest ↓SNYSanofi3.5571 of 5 stars$51.98-1.0%$63.33+21.8%+8.4%$131.32B$45.17B20.8891,600GSKGSK1.9581 of 5 stars$38.70-0.6%$40.58+4.9%-11.4%$79.84B$31.53B24.3490,100Trending NewsAnalyst RevisionTAKTakeda Pharmaceutical2.7773 of 5 stars$14.58+1.1%N/A+11.2%$46.38B$4.58T36.4447,300Short Interest ↑ARGXargenx3.255 of 5 stars$587.61+1.1%$698.11+18.8%+57.3%$35.88B$2.58B-667.74650Positive NewsONCBeigene2.9392 of 5 stars$241.43+1.1%$319.00+32.1%N/A$23.91B$4.18B-29.309,000BNTXBioNTech2.6234 of 5 stars$98.68-0.4%$141.73+43.6%+3.6%$23.72B$2.75B-46.993,080Analyst ForecastGap DownTEVATeva Pharmaceutical Industries2.6871 of 5 stars$16.95+0.0%$24.43+44.2%+8.1%$19.21B$16.62B-11.6936,800Trending NewsAnalyst UpgradeShort Interest ↑Gap DownSMMTSummit Therapeutics3.0962 of 5 stars$25.85+0.3%$37.40+44.7%+989.5%$19.20B$700,000.00-92.32110Positive News Related Companies and Tools Related Companies Novo Nordisk A/S Alternatives Novartis Alternatives Sanofi Alternatives GSK Alternatives Takeda Pharmaceutical Alternatives argenx Alternatives Beigene Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Summit Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AZN) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.